PMID- 36638352
OWN - NLM
STAT- MEDLINE
DCOM- 20230117
LR  - 20230117
IS  - 1543-0790 (Print)
IS  - 1543-0790 (Linking)
VI  - 21
IP  - 1
DP  - 2023 Jan
TI  - Treatment landscape of advanced high-grade neuroendocrine neoplasms.
PG  - 16-26
AB  - Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) 
      neuroendocrine malignancies that comprise both rapidly proliferating, 
      well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated 
      neuroendocrine carcinomas (NEC). The phenotypic differences between NET G3 and 
      NEC stem from differences in their underlying genomic alterations. As a result of 
      these differences, NET G3 is molecularly, radiologically, and prognostically 
      distinct from NEC. The optimal management of NET G3 and NEC is currently being 
      refined through clinical trials that focus on NET G3 and NEC as separate 
      entities. This review aims to summarize the current understanding of NEN G3 by 
      distinguishing between NET G3 and NEC and describing the clinical implications 
      associated with each.
FAU - Alheraki, Samee Zane
AU  - Alheraki SZ
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
FAU - Almquist, Daniel R
AU  - Almquist DR
AD  - Division of Hematology and Medical Oncology, Sanford Health, Fargo, North Dakota.
FAU - Starr, Jason S
AU  - Starr JS
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida.
FAU - Halfdanarson, Thorvardur R
AU  - Halfdanarson TR
AD  - Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
FAU - Sonbol, Mohamad Bassam
AU  - Sonbol MB
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Adv Hematol Oncol
JT  - Clinical advances in hematology & oncology : H&O
JID - 101167661
SB  - IM
MH  - Humans
MH  - Neoplasm Grading
MH  - *Neuroendocrine Tumors/diagnosis/genetics/therapy
MH  - *Pancreatic Neoplasms/drug therapy
MH  - *Carcinoma, Neuroendocrine/pathology
MH  - *Stomach Neoplasms/pathology
MH  - *Intestinal Neoplasms/pathology
EDAT- 2023/01/14 06:00
MHDA- 2023/01/18 06:00
CRDT- 2023/01/13 16:22
PHST- 2023/01/13 16:22 [entrez]
PHST- 2023/01/14 06:00 [pubmed]
PHST- 2023/01/18 06:00 [medline]
PST - ppublish
SO  - Clin Adv Hematol Oncol. 2023 Jan;21(1):16-26.